Affymax Completes Phase III Program for Hematide to Treat Anemia

Affymax, Inc. Monday announced completion of treatment and follow-up of patients with anemia due to chronic renal failure enrolled in the four-trial, Phase 3 clinical program for the investigational drug Hematide.
Fox Business